Bussiness Ideas
Our startup operates a dual-stream business model that integrates affordable molecular diagnostics with regenerative therapeutic development, leveraging deep-tech and AI-driven innovations.
The diagnostic arm focuses on developing low-cost, high-specificity liquid biopsy panels for early cancer and rare disease detection using cfDNA, RNA and epigenetic markers identified through database research, machine learning analytics and validation.
Initially targeting Head and Neck Squamous Cell Carcinoma (HNSCC), the diagnostic platform provides rapid, actionable results at a fraction of the cost of conventional NGS-based tests. Revenue will be generated through the sale of test kits and AI-powered analysis services to hospitals, diagnostic labs, and research institutions.
The platform is designed to be scalable, enabling expansion to other cancers and disease contexts. The therapeutic arm focuses on quiescent stem cell (qSC) biology, using CRISPR-based genome modulation and AI-assisted pathway control to develop regenerative and anti-relapse therapeutics for oncology and ischemic disease. Revenue will come from strategic collaborations, licensing, and co-development agreements with pharmaceutical and biotechnology companies.
By combining frugal diagnostics with cutting-edge regenerative therapeutics, our model ensures both near-term sustainability and long-term innovation growth. The company leverages a computational-experimental feedback loop, integrating omics data, AI, and gene-editing technologies, to deliver affordable, scalable, and clinically impactful solutions from bench to bedside.
Show More
